Gastrografin®

 

(diatrizoate meglumine and diatrizoate sodium solution USP)

Gastrografin® (diatrizoate meglumine and diatrizoate sodium solution USP) is a palatable lemon-flavored, water-soluble iodinated radiopaque contrast medium for oral or rectal administration used for radiographic examination of segments of the gastrointestinal tract, particularly in cases in which barium examinations would be potentially risky. Gastrografin is also used for examinations for foreign bodies on the pharynx and esophagus and disorders of the swallowing mechanism.

Contact us

Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

By checking this box and clicking the submit button of this page, I certify that I am a healthcare professional, and give permission for Bracco Imaging S.p.A., or parties acting on its behalf, to contact me with information regarding Bracco Imaging S.p.A., products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Imaging S.p.A., except for the agents or representatives processing this request.

Indications and Usage:

GASTROGRAFIN® (diatrizoate meglumine and diatrizoate sodium solution) is indicated for radiographic examination of the gastrointestinal tract, particularly in cases in which barium suspensions would be potentially risky as well as examinations for foreign bodies in the pharynx and esophagus and disorders of the swallowing mechanism. 

 

For additional information, please consult product monograph on Health Canada website: 

https://pdf.hres.ca/dpd_pm/00065640.PDF

 

IMPORTANT SAFETY INFORMATION:

Not for parenteral use; do not inject.  For oral or rectal administration only.  It should be kept in mind that serious or anaphylactoid reactions that may occur with intravascular administration of radiopaque contrast agents and are theoretically possible following administration by other routes.  Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever and food allergies).